The safety of hormone therapy during pregnancy. Joint statement by experts in reproductive medicine, obstetrics and gynecology, endocrinology, clinical pharmacology, neonatology and pediatrics

The article is republished in order to expand the audience. The article was published earlier in the Akusherstvo i Ginekologiya (Russian Federation): Sukhikh GT, Serov VN, Artymuk NV, Andreeva MD, Bazina MI, Baranov II, Bashmakova NV, Bezhenar VF, Belotserkovtseva LD, Geppe NA, Dolgushina NV, Zaretskaya NV, Zakharova IN, Zubkov VV, Enkova EV, Yesayan RM, Katkova NYu, Kvashnina EV, Kogan IYu, Korsak VS, Krasnopolskaya KV, Kukarskaya II, Molchanova IV, Nazarenko TA, Pestova TI, Podzolkova NM, Saveljeva IV, Sazonova AI, Semenov YuA, Tapilskaya NI, Tetruashvili NK, Tiselko AV, Fadeev VV, Shamugia NL, Shakhova MA, Shikh EV, Yarmolinskaya MI. The safety of hormone therapy during pregnancy. Joint statement by experts in reproductive medicine, obstetrics and gynecology, endocrinology, clinical pharmacology, neonatology and pediatrics Akusherstvo i Ginekologiya (Russian Federation). 2024;(8):196–206. (In Russ.) https://doi.org/10.18565/aig.2024.201.

1. WHO. Launch of the report on Women and health: today’s evidence, tomorrow’s agenda. WHO; 2009.

2. Miscarriage. Clinical guidelines of RSOG. 2021. (in Russian).

3. Miscarriage. Clinical guidelines of RSOG. 2024. (in Russian).

4. Female infertility. Clinical guidelines of RSOG. 2021. (in Russian).

5. Female infertility. Clinical guidelines of RSOG. 2024. (in Russian).

6. Isthmico-cervical insufficiency. Clinical guidelines of RSOG. 2021. (in Russian).

7. Habitual miscarriage. Clinical guidelines of RSOG. 2022. (in Russian).

8. Normal pregnancy. Clinical guidelines of RSOG. 2023. (in Russian).

9. Multiple pregnancy. Clinical guidelines of RSOG. 2021. (in Russian).

10. Venous complications during pregnancy and postpartum. Obstetric thromboembolism. Clinical guidelines of RSOG. 2022. (in Russian).

11. Eclampsia. Edema, proteinuria, and hypertensive disorders during pregnancy, delivery, and postpartum. Clinical guidelines of RSOG. 2021. (in Russian).

12. Insufficient growth of the fetus, requiring the provision of medical care to the mother (fetal growth retardation). Clinical guidelines of RSOG. 2022. (in Russian).

13. Shehata H., Elfituri A., Doumouchtsis S.K., Zini M.E., Ali A., Jan H. et al. FIGO Good Practice Recommendations on the use of progesterone in the management of recurrent first-trimester miscarriage. Int. J. Gynaecol. Obstet. 2023; 161 Suppl 1: 3-16. https://dx.doi.org/10.1002/ijgo.14717.

14. Recurrent Pregnancy Loss. Guideline of European Society of Human Reproduction and Embryology. 2023.

15. NICE. Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE guideline [NG126]. Published: 17 April 2019 Last updated: 29 August 2023.

16. Bosch E., Broer S., Griesinger G., Grynberg M., Humaidan P., Kolibianakis E. et al.; ESHRE Guideline Group on Ovarian Stimulation. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum. Reprod. Open. 2020; 2020(2):hoaa009. https://dx.doi.org/10.1093/hropen/hoaa009.

17. Federal Law of 21.11.2011 N 323-FZ (as amended by 02.07.2021) “On the Basics of Protecting the Health of Citizens in the Russian Federation” (amended and supplemented, entry by virtue of 01.10.2021) (in Russian).

18. Type 1 diabetes mellitus in adults. Clinical guidelines of RAE. 2022. (in Russian).

19. Gestational diabetes mellitus. Draft of Clinical guidelines of RAE, RSOG. 2020. (in Russian).

20. Congenital adrenal cortex dysfunction (adrenogenital syndrome). Clinical guidelines of RAE, RSOG. 2021 (in Russian).

21. Гипотиреоз. Клинические рекомендации РАЭ. 2021. [Hypothyroidism. Clinical guidelines of RAE. 2021. (in Russian)].

22. Koren G., Barer Y., Cem Kaplan Y. Fetal safety of medications used in treating infertility. Expert. Rev. Clin. Pharmacol. 2020; 13(9): 991-1000. https://dx.doi.org/10.1080/17512433.2020.1803738. Retraction in: Expert Rev. Clin. Pharmacol. 2022; 15(3): i. https://dx.doi.org/10.1080/17512433.2022.2044624.

23. Zaqout M., Aslem E., Abuqamar M., Abughazza O., Panzer J., De Wolf D. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr. Cardiol. 2015; 36(7): 1483-8. https://dx.doi.org/10.1007/s00246-015-1190-9.

24. Henry A., Santulli P., Bourdon M., Treluyer J.M., Chouchana L. O-150 Birth defects reporting and the use of oral dydrogesterone in assisted reproductive technology: a global pharmacovigilance study. Hum. Rep. 2023; 38(Suppl_1): dead093.77. https://dx.doi.org/10.1093/humrep/dead093.177.

25. Li L., Wang K., Wang M., Tao J., Li X., Liu Z. et al. The maternal drug exposure birth cohort (DEBC) in China. Nat. Commun. 2024; 15(1): 5312. https://dx.doi.org/10.1038/s41467-024-49623-0.

26. van der Vet P.E., Nijveen H. Propagation of errors in citation networks: a study involving the entire citation network of a widely cited paper published in, and later retracted from, the journal Nature. Res. Integr. Peer Rev. 2016; 1: 3. https://dx.doi.org/10.1186/s41073-016-0008-5.

27. Pomerantseva E.A., Dokshukina A.A., Degtyareva A.V., Maslennikov D.N., Trofimov D.Yu., Degtyarev D.N. Criteria of phenotype assessment of newborn for the group formation with increased risk of genetic diseases. Neonatology: News, Opinions, Training. 2022; 10(4): 47-53. (in Russian). https://dx.doi.org/10.33029/2308-2402-2022-10-4-47-53.

28. Russian Association for Human Reproduction. Register of ART of Russia. 2021 Report. (in Russian).

29. Bosch E., De Vos M., Humaidan P. The future of cryopreservation in assisted reproductive technologies. Front Endocrinol (Lausanne). 2020; 11: 67. https://dx.doi.org/10.3389/fendo.2020.00067.

30. Ernstad E.G., Wennerholm U.-B., Khatibi A., Petzold M., Bergh C. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles. Am. J. Obstet. Gynecol. 2019; 221(2): 126.e1-126.e18. https://dx.doi.org/10.1016/j.ajog.2019.03.010.

31. Bashmakova N.V., Lokshin V.N., Isenova S.Sh., Khramtsova A.Yu., Dankova I.V., Ryabukhin I.V. Comparative analysis of the effectiveness of programs and perinatal outcomes after frozenthawed embryo transfer depending on post-transfer support medications. Obstetrics and Gynecology. 2023; (7): 103-8. (in Russian). https://dx.doi.org/10.18565/aig.2023.161.

32. Product Characteristics of Estrogel® gel transdermal 0.6 mg/g (vials) 80 g, LP-No.(005618)-(RG-RU) dated 29/05/2024. (in Russian).

33. Instructions for the medical use of the drug Proginova® dated 14/06/2023. (in Russian).

34. Instructions for the medical use of the drug Divigel® dated 05/05/2023. (in Russian).

35. Russian Association of Human Reproduction. Use of estrogens in ART programs. Scientific and practical recommendations. 2015. 24 p. (in Russian).

36. Krieg S.A., Henne M.B., Westphal L.M. Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies. Fertil. Steril. 2008; 90(1): 65-70. https://dx.doi.org/10.1016/j.fertnstert.2007.06.014.

37. Stoop D., Baumgarten M., Haentjens P., Polyzos N.P., De Vos M., Verheyen G. et al. Obstetric outcome in donor oocyte pregnancies: a matched-pair analysis. Reprod. Biol. Endocrinol. 2012; 10: 42. https://dx.doi.org/10.1186/1477-7827-10-42.

38. Bashmakova N.V., Novoselova E.N., Nazarenko T.A., Ovchinnikova M.M., Fetisova Yu.A., Gergert E.V., Ganikhina M.A., Valiullina N.G., Golovina E.O., Shcherban M.R., Semikhin A.S., Polzikov M.A., Blinov D.V. Real clinical practice of infertility treatment in Russia: a collective opinion of 425 reproductologists. Obstetrics, Gynecology and Reproduction. 2023; 17(6): 680-706. (in Russian). https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2023.468.

39. Shikh E.V. Comparative clinical pharmacological aspects of oral and transdermal dosage forms of estrogens. Obstetrics and Gynecology: News, Opinions, Training. 2016; 1: 41-6. (in Russian).

40. Tetruashvili N.K., Serov V.N. Gestagens in high-risk pregnancy. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10(2): 31-8. (in Russian). https://dx.doi.org/10.33029/2303-9698-2022-10-2-31-38.

41. Sukhikh G.Т., Adamyan L.V., Serov V.N., et al. Resolution of the Advisory Board on the subject: Multicenter OpenLabel Observational Program to Research on Predictors of Pregnancy Rate in Assisted Reproductive Technology in the Russian Population According to Actual International and National Guidelines (IRIS study). Obstetrics and Gynecology. 2019; (12): 218-25. (in Russian). https://dx.doi.org/10.18565/aig.2019.12.218-225.

42. Tetruashvili N.K., Shih E.V. Efficacy of dydrogesterone in threatened miscarriage: a systematic review and meta-analysis. Doctor. Ru. 2022; 21(5): 53-61. (in Russian). https://dx.doi.org/10.31550/1727-2378-2022-21-5-53-61.

43. Product Characteristics of Dufaston® 10 mg film-coated tablets, LP-No.(001546)-(RG-RU) dated 22/03/2023 (in Russian).

44. Product Characteristics of Utrogestan® 200 mg/1 mg capsules, LP-No. (005733)-(RG-RU) dated 11/06/2024 (in Russian).

45. Schindler A.E. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009; 65(Suppl 1): S3-S11. https://dx.doi.org/10.1016/j.maturitas.2009.10.011.

46. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W. et al. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80. https://dx.doi.org/10.1016/j.maturitas.2008.11.013.

47. Rižner T.L., Brožič P., Doucette C., Turek-Etienne T., Müller-Vieira U., Sonneveld E. et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76(6): 607-15. https://dx.doi.org/10.1016/j.steroids.2011.02.043.

48. Bitsadze V.O., Akinshina S.V., Khizroeva J.Kh., Makatsariya N.A., Stuleva N.S., Mashkova T.Ya. The patho genetic basis for using natural progesterone therapy in obstetric practice. Obstetrics, Gynecology and Reproduction. 2014; 8(2): 79-88. (in Russian).

49. Coomarasamy A., Williams H., Truchanowicz E., Seed P.T., Small R., Quenby S. et al. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages – a randomised, doubleblind, placebo-controlled, international multicentre trial and economic evaluation. Health Technol. Assess. 2016; 20(41): 1-92. https://dx.doi.org/10.3310/hta20410.

50. Coomarasamy A., Devall A.J., Cheed V., Harb H., Middleton L.J., Gallos I.D. et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N. Engl. J. Med. 2019; 380(19): 1815-24. https://dx.doi.org/10.1056/NEJMoa1813730.

51. Griesinger G., Tournaye H., Macklon N., Petraglia F., Arck P., Blockeel C. et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod. Biomed. Online. 2019; 38(2): 249-59. https://dx.doi.org/10.1016/j.rbmo.2018.11.017.

52. Kapustin R.V., Arzhanova O.N., Bespalova O.N. Exogenous progesterone as a factor for the development of gestational diabetes mellitus. Russian Bulletin of Obstetrician-Gynecologist. 2019; 19(1): 38-45. (in Russian). https://dx.doi.org/10.17116/rosakush20191901138.

53. Areeruk W., Phupong V. A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor. Sci. Rep. 2016; 6: 20638. https://dx.doi.org/10.1038/srep20638.

54. Zheng Z., Armfield B.A., Cohn M.J. Timing of androgen receptor disruption and estrogen exposure underlies a spectrum of congenital penile anomalies. Proc. Natl. Acad. Sci. U. S. A. 2015; 112(52): E7194-203. https://dx.doi.org/10.1073/pnas.1515981112.

55. Ott J., Egarter C., Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol. Endocrinol. 2022; 38(4): 279-87. https://dx.doi.org/10.1080/09513590.2021.2016692.

56. Tournaye H., Sukhikh G.T., Kahler E., Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum. Reprod. 2017; 32(10): 2152. https://dx.doi.org/10.1093/humrep/dex266.

57. Griesinger G., Blockeel C., Sukhikh G.T., Patki A., Dhorepatil B., Yang D.Z. et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum. Reprod. 2018; 33(12): 2212-21. https://dx.doi.org/10.1093/humrep/dey306.

58. Griesinger G., Blockeel C., Kahler E., Pexman-Fieth C., Olofsson J.I., Driessen S. et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020; 15(11): e0241044. https://doi.org/10.1371/journal.pone.0241044.

59. Yang W., Chi H., Yang R., Liu P., Li R., Qiao J. et al. Congenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization. Fertil. Steril. 2023; 120 (Issue 4, Supplement): E72. https://dx.doi.org/10.1016/j.fertnstert.2023.08.222.

60. https://pubmed.ncbi.nlm.nih.gov/?term=dydrogesterone+ivf

61. Patki A. Role of dydrogesterone for luteal phase support in assisted reproduction. Reprod. Sci. 2024; 31(1): 17-29. https://dx.doi.org/10.1007/s43032-023-01302-z.

62. Katalinic A., Noftz M.R., Garcia-Velasco J.A., Shulman L.P., van den Anker J.N., Strauss Iii J.F. No additional risk of congenital anomalies after firsttrimester dydrogesterone use: a systematic review and meta-analysis. Hum. Reprod. Open. 2024; 2024(1): hoae004. https://dx.doi.org/10.1093/hropen/hoae004.

63. Quadros R., Puppalwar G., Mane A., Mehta S. Absence of evidence is not evidence of absence for first trimester dydrogesterone-induced birth defects. Hum. Reprod. Open. 2024; 2024(2): hoae030. https://dx.doi.org/10.1093/hropen/hoae030.

64. Katalinic A. Reply: Absence of evidence is not evidence of absence for first trimester dydrogesterone-induced birth defects. Hum. Reprod. Open. 2024; 2024(2): hoae031. https://dx.doi.org/10.1093/hropen/hoae031.

65. Zhukova D.Y., Kovalskaya G.N. The original and generic drugs in medical therapy. Siberian Medical Journal. 2011; 7: 96-102. (in Russian).

66. Sokolov A., Kukes V., Bunatyan N., Rodina T., Prokofiev A., Arkhipov V., Krasnykh L., Sokova E. Therapeutic equivalence, bioequivalence and interchangeability of medicinal products. Vrach. 2015; (10): 32-5. (in Russian).

67. [Y0001004 Dydrogesterone European Pharmacopoeia (EP) Reference Standard.

68. USP Reference Standart Dydrogesterone (9β,10α-Pregna-4,6-diene-3,20-dione), USP Catalog No.: 1231003, USP Lot No.: R161T0.

69. Zarei A., Sohail P., Parsanezhad M.E., Alborzi S., Samsami A., Azizi M. Comparison of four protocols for luteal phase support in frozen-thawed embryo transfer cycles: a randomized clinical trial. Arch. Gynecol. Obstet. 2017; 295(1): 239-46. https://dx.doi.org/10.1007/s00404-016-4217-4.

70. New M.I., Ghizzoni L., Meyer-Bahlburg H., Khattab A., Reichman D., Rosenwaks Z. Fertility in patients with nonclassical congenital adrenal hyperplasia. Fertil. Steril. 2019; 111(1): 13-20. https://dx.doi.org/10.1016/j.fertnstert.2018.11.023.

71. Pavlidi O., Kolibianakis E.M. Fertility treatment in women with classical and nonclassical congenital adrenal hyperplasia. In: Ertorer M.E., eds. Fertility and reproductive outcomes in different forms of congenital adrenal hyperplasia. Springer, Cham. 2021. https://dx.doi.org/10.1007/978-3-030-82591-1_8.

72. Instructions for the medical use of the drug Prednisolone tablets 5 mg, LP-No.(002720)-(RG-RU) dated 10/07/2023. (in Russian).

73. Instructions for the medical use of the drug Metypred tablets 4 mg, P 015709/01 dated 25/01/2024. (in Russian)].

74. Slob E.M.A.., Termote J.U.M., Nijkamp J.W., van der Kamp H.J., van den Akker E.L.T. Safety of antenatal predniso(lo)ne and dexamethasone on fetal, neonatal and childhood outcomes: a systematic review. J. Clin. Endocrinol. Metab. 2024; 109(4): e1328-e1335. https://dx.doi.org/10.1210/clinem/dgad547.

75. Taylor P.N., Minassian C., Rehman A., Iqbal A., Draman M.S., Hamilton W. et al. TSH levels and risk of miscarriage in women on long-term levothyroxine: a community-based study. J. Clin. Endocrinol. Metab. 2014; 99(10): 3895-902. https://dx.doi.org/10.1210/jc.2014-1954.

76. Kuroda K., Ikemoto Y., Horikawa T., Moriyama A., Ojiro Y., Takamizawa S. et al. Novel approaches to the management of recurrent pregnancy loss: The OPTIMUM (OPtimization of Thyroid function, Thrombophilia, Immunity, and Uterine Milieu) treatment strategy. Reprod. Med. Biol. 2021; 20(4): 524-36. https://dx.doi.org/10.1002/rmb2.12412.

77. Product Characteristics of L-Thyroxin 50 Berlin-Chemie 50 µg tablets, LP-No.(006003)-(RG-RU) dated 26/06/2024 (in Russian).

78. Sankoda A., Suzuki H., Imaizumi M., Yoshihara A., Kobayashi S., Katai M. et al. Effects of levothyroxine treatment on fertility and pregnancy outcomes in subclinical hypothyroidism: a systematic review and metaanalysis of randomized controlled trials. Thyroid. 2024; 34(4): 519-30. https://dx.doi.org/10.1089/thy.2023.0546.

79. Gottwald-Hostalek U., Kahaly G.J. Optimizing levothyroxine treatment for subclinical hypothyroidism during pregnancy. Curr. Med. Res. Opin. 2024; 40(1): 43-9. https://dx.doi.org/10.1080/03007995.2023.2276120.

80. Leng T., Li X., Zhang H. Levothyroxine treatment for subclinical hypothyroidism improves the rate of live births in pregnant women with recurrent pregnancy loss: a randomized clinical trial. Gynecol. Endocrinol. 2022; 38(6): 488-94. https://dx.doi.org/10.1080/09513590.2022.2063831.

81. Luo J., Yuan J. Effects of levothyroxine therapy on pregnancy and neonatal outcomes in subclinical hypothyroidism. Int. J. Gen. Med. 2022; 15: 6811-20. https://dx.doi.org/10.2147/IJGM.S366981.

82. Dedov I.I., Shestakova M.V., Mayorov A.Yu., eds. Standards of specialized diabetes care. 11th Edition. Moscow; 2023: 148-61. (in Russian).

83. Dedov I.I., Melnichenko G.A., Burumkulova F.F., ed. Endocrine diseases and pregnancy in questions and answers. A guide for doctors. M.: E-noto; 2024. 336 p. (in Russian).

84. Dedov I.I., Shestakova M.V., Mayorov A.Y., Shamkhalova M.S., Sukhareva O.Yu., Galstyan G.R., Tokmakova A.Y., Nikonova T.V., Surkova E.V., Kononenko I.V., Egorova D.N., Ibragimova L.I., Shestakova E.A., Klefortova I.I., Sklyanik I.A., Yarek-Martynova I.Ya., Severina A.S., Martynov S.A., Vikulova O.K., Kalashnikov V.Y., Bondarenko I.Z., Gomova I.S., Starostina E.G., Ametov A.S., Antsiferov M.B., Bardymova T.P., Bondar I.A., Valeeva F.V., Demidova T.Y., Mkrtumyan A.M., Petunina N.A., Ruyatkina L.A., Suplotova L.A., Ushakova O.V., Khalimov Yu.Sh. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020; 23(2S): 4-102. (in Russian). https://dx.doi.org/10.14341/DM12507.

85. Instructions for the medical use of the drug NovoRapid® Penfill® dated 24/01/2020. (in Russian).

86. Product Characteristics of Lantus® SoloStar® 100 U/ mL solution for subcutaneous injection, LP-No.(000207)-(RG-RU) dated13/06/2024. (in Russian).

87. Feig D.S., Donovan L.E., Corcoy R., Murphy K.E., Amiel S.A., Hunt K.F. et al.; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017; 390 (10110): 2347-59. https://dx.doi.org/10.1016/S0140-6736(17)32400-5.

88. Lemaitre M., Faiz K., Baudoux F., Subtil D., Vambergue A. Intermittently scanned continuous glucose monitoring is associated with lower spontaneous abortion rate compared with conventional blood glucose monitoring in pregnant women with type 1 diabetes: An observational study. Diab. Vasc. Dis. Res. 2022; 19(6): 14791641221136837. https://dx.doi.org/10.1177/14791641221136837.

89. Majewska A., Stanirowski P.J., Tatur J., Wojda B., Radosz I., Wielgos M. et al. Flash glucose monitoring in gestational diabetes mellitus (FLAMINGO): a randomised controlled trial. Acta Diabetol. 2023; 60(9): 1171-7. https://dx.doi.org/10.1007/s00592-023-02091-2.

90. García-Moreno R.M., Benítez-Valderrama P., Barquiel B., González Pérez-deVillar N., Hillman N., Lora Pablos D. et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabet Med. 2022; 39(1): e14703. https://dx.doi.org/10.1111/dme.14703.

91. Scott E.M., Bilous R.W., Kautzky-Willer A. Accuracy, user acceptability, and safety evaluation for the FreeStyle Libre Flash Glucose Monitoring System when used by pregnant women with diabetes. Diabetes Technol. Ther. 2018; 20(3): 180-8. https://dx.doi.org/10.1089/dia.2017.0386.

92. Federal State Statistics Service (Rosstat). https://rosstat.gov.ru/folder/12781 (in Russian).

93. Christianson A. Howson C.P., Modell B. March of Dimes Global Report of Birth Defects: The Hidden Toll of Dying and Disabled Children. White Plains, New York; 2006.

94. ART: choosing a strategy. Innovative pharmacotherapy. 2021; 3: 30-4. (in Russian).

95. Reproductology: Search for innovative solutions. Innovative pharmacotherapy. 2022; 5(9): 32-8. (in Russian).

96. Kuznetsova I.V., Grigoryan A.N., Geppe N.A., KovsalZaytsev A.A. Features of the psychosexual development of children born to women who received hormonal treatment during pregnancy. Gynecology. 2015; 17(2): 45-9. (in Russian).

97. Serov V.N., Nazarenko T.A., Tapilskaya N.I., Tetruashvili N.K., Shikh E.V. Progestogens safety in the treatment of infertility and during pregnancy: new data in 2023. Position of the Russian Society of Obstetricians and Gynecologists. Obstetrics and Gynecology. 2023; (8): 236-9. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.196.